Biotechnology

Bicara Therapeutics

Bicara Therapeutics released FY2026 Q1 earnings on May 11 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9257 (forecast USD -0.6484)

Bicara Therapeutics to Release FY2026 Q1 Earnings on May 11 Pre-Market EST, Forecast EPS USD -0.6508

Bicara Therapeutics released FY2025 Annual Earnings on March 30 Pre-Market (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -2.523 (Forecast: USD -2.5136)

Bicara Therapeutics released FY2025 Q4 earnings on March 30 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6779 (forecast USD -0.67)

Bicara Therapeutics to Release FY2025 Q4 Earnings on March 30 Pre-Market EST, Forecast EPS -0.67 USD

Bicara Therapeutics released FY2025 Q3 earnings on November 10 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6658 (forecast USD -0.5662)

Bicara Therapeutics released FY2025 9 Months Earnings on November 10 (EST), actual revenue USD 0, actual EPS USD -1.8446

Bicara Therapeutics released FY2025 Q2 earnings on August 12 EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5021 (forecast USD -0.535)

Bicara Therapeutics released FY2025 Semi-Annual Earnings on August 12, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.1786

Bicara Therapeutics released FY2025 Q1 earnings on May 13, 2025, EST: Actual Revenue USD 0 (Forecast USD 0), Actual EPS USD -0.6766 (Forecast USD -0.4166)

Bicara Therapeutics released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.385 USD (forecast -0.328 USD)

Bicara Therapeutics released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.0459 USD (forecast -2.338 USD)

Bicara Therapeutics released FY2024 Q3 earnings on November 12 (EST), actual EPS -1.6035 (forecast -0.43), revenue 0

Bicara Therapeutics released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of 0 and EPS of -39.7902

Bicara Therapeutics released FY2023 Q4 earnings on September 6, 2024 (EST) with actual revenue of 0 USD and EPS of -19.7464 USD

Bicara Therapeutics released FY2023 Cumulative 3Q Earnings on September 6, 2024 (EST), with Revenue of 0 USD and EPS of -68.8052

Bicara Therapeutics released FY2024 Semi-Annual earnings on August 22 (EST), actual revenue USD 0, actual EPS USD -38.1867

Bicara Therapeutics released FY2024 Q1 earnings on August 22, 2024 (EST) with actual revenue of USD 0 and EPS of USD -18.9432

Bicara Therapeutics released FY2024 Q2 earnings on August 22 (EST) with actual revenue of USD 0 and EPS of USD -19.0121

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

Capstone

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

MetaVia

BCAX

Bicara Therapeutics (NASDAQ: BCAX) announced that its lead cancer drug candidate, ficerafusp alfa, is on track for pivotal data in head and neck cancer by mid-2026. The company presented its development strategy at the Bank of America Healthcare Conference, focusing on large-molecule bifunctional antibodies. Ficerafusp alfa targets EGFR and TGF-beta, aiming for effective tumor delivery. The Phase 3 study is set to randomize patients to ficerafusp alfa plus pembrolizumab versus pembrolizumab monotherapy, with top-line data expected in mid-2026. Bicara's pivotal program targets HPV-negative head and neck cancer, with a focus on improving response rates and overall survival.

Market Beat

VanEck Biotech ETF

Bank of America

Genmab A/S

Merus BV

Johnson & Johnson

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Wedbush analyst has maintained a Buy rating on Bicara Therapeutics Inc. (BCAX) with a price target of $30.00, while the shares closed at $22.38. The analyst consensus is a Strong Buy with an average price target of $30.99, indicating a potential upside of 38.47%. Additionally, Stifel Nicolaus also holds a Buy rating with a price target of $46.00.

Tip Ranks

Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

REPL

ARKG

LABU

Bicara Therapeutics has appointed Chris Sarchi as its chief commercial officer as it prepares for a potential accelerated approval of its cancer drug next year. Sarchi, previously at Replimune and Sanofi, joins at a crucial time following significant layoffs after an FDA rejection of a melanoma drug. Bicara aims to leverage a $362 million IPO to support trials for its lead asset, ficerafusp alfa, currently in a pivotal trial for head and neck cancer. Sarchi's role will be pivotal in transitioning Bicara into a commercial biotech.

Fiercepharma

Replimune

Sanofi

iShares Biotechnology ETF

VG Health

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

iShares US Pharma

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

Bicara Therapeutics hires Replimune, Sanofi alum as CCO

Bicara Therapeutics Inc. (BCAX) reported a net loss of $56.21 million for Q1 2026, compared to a loss of $36.85 million in Q1 2025. The company raised $161.8 million from a public offering and has $539.80 million in cash and securities. Bicara is advancing its lead candidate, ficerafusp alfa, in trials for HPV-negative head and neck cancer, with enrollment expected to complete by year-end 2026. The stock is currently trading at $23.38, up 3.54%.

nasdaq

Nasdaq

Bicara Records $56 Mln Loss In Q1; Provides Updates On Ficerafusp Alfa Trials

Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results.

benzinga_article

Earnings Watch

Bicara Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Bicara Therapeutics (NASDAQ:BCAX) is set to announce its Q1 2026 earnings on May 12, with analysts expecting a loss of $0.64 per share. The company recently reported a loss of $0.68 per share for the previous quarter, exceeding estimates. The stock is currently trading at $22.49, with a market cap of $1.48 billion. Recent insider sales and significant institutional investments have been noted. Analysts have varied price targets, with HC Wainwright raising theirs to $42.00, while others maintain a range between $16.00 and $30.00 for the stock.

Bicara Therapeutics(BCAX.US)